Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6043 alone and in combination with bevacizumab and/or chemotherapy in advanced solid tumors
CTR20263595Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6043 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
SYS6043
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20263595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263595.